China Stock Alerts
BeiGene, Ltd.
NASDAQ:
HK:
BGNE
6160
BeiGene's mission is to build the first next-generation biopharmaceutical company, one that expands the highest quality therapies to billions more people through courage, persistent innovation, and challenging the status quo.
BeiGene is passionate about its people, science, and creating a lasting impact. These priorities are of utmost importance to the organization. BeiGene strives to build a global organization recognized for its impact in cancer research and drug development, talented people, and integrity. As part of the global clinical development program, BeiGene is enrolling patients in 34 countries to participate in clinical trials.
Key Facts
Auditor
Public Listing
Domicile
HQ/Management
Location of Key Operations
IR Contact
Ernst & Young LLP
IPO (February 3, 2016)
Cayman Islands
Changping, Beijing, China
Craig West, Internal
857-302-5189
Analyst Coverage
Latest News
September 13, 2021: BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell Carcinoma
June 22, 2021: China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma | BeiGene LTD
June 7, 2021: BeiGene Presents Clinical Data from Two Phase 2 Trials of Pamiparib at the 2021 ASCO Annual Meeting | BeiGene LTD
May 19, 2021: BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting | BeiGene LTD
May 10, 2021: BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress | BeiGene LTD
May 6, 2021: BeiGene Reports First Quarter 2021 Financial Results | BeiGene LTD
May 3, 2021: BEIGENE 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS PROXY STATEMENT/ CIRCULAR
April 26, 2021: 2020 ANNUAL REPORT
April 22, 2021: DATE OF AUDIT COMMITTEE MEETING
April 9, 2021: BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
April 9, 2021: FORM 2 - CORPORATE SUBSTANTIAL SHAREHOLDER NOTICE
April 8, 2021: BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia
April 8, 2021: BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
April 8, 2021: OVERSEAS REGULATORY ANNOUNCEMENT – INDEPENDENT DIRECTOR COMPENSATION POLICY
April 7, 2021: BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China
April 6, 2021: GRANT OF SHARE OPTIONS
April 6, 2021: Next Day Disclosure Return
April 1, 2021: FORM 2 - CORPORATE SUBSTANTIAL SHAREHOLDER NOTICE
March 30, 2021: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020
March 30, 2021: BeiGene Announces New Chief Financial Officer, Julia Wang
March 23, 2021: FORM 2 - CORPORATE SUBSTANTIAL SHAREHOLDER NOTICE
March 18, 2021: Boston Immune Technologies and Therapeutics Raises $10M Series A Financing
March 17, 2021: FORM 3A - DIRECTOR/CHIEF EXECUTIVE NOTICE - INTERESTS IN SHARES OF LISTED CORPORATION
March 16, 2021: FORM 2 - CORPORATE SUBSTANTIAL SHAREHOLDER NOTICE
March 11, 2021: FORM 2 - CORPORATE SUBSTANTIAL SHAREHOLDER NOTICE
March 10, 2021: First Patient Treated in Ivy Brain Tumor Center’s Phase 0 Clinical Trial of Pamiparib in Newly Diagnosed and Recurrent Glioblastoma
March 10, 2021: BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021
March 4, 2021: Monthly Return of Equity Issuer on Movements in Securities
March 3, 2021: UPDATE REGARDING RECENT BUSINESS DEVELOPMENTS
March 2, 2021: Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia
March 1, 2021: VOLUNTARY ANNOUNCEMENT – UPDATE REGARDING RECENT BUSINESS DEVELOPMENTS
February 26, 2021: BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan
February 18, 2021: Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
February 17, 2021: BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström’s Macroglobulinemia
January 27, 2021: BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma
January 25, 2021: EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for
January 13, 2021: China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer
January 11, 2021: BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab
January 7, 2021: BeiGene to Present at the J.P. Morgan 39th Annual Healthcare Conference